Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 10/20 | 0.65 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.65 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20488466 | 0.86 | FUCA1 (0.60) | S1PR5S1PR1FUCA1ALDH1A1 | |
| SCHEMBL51920 | 0.85 | S1PR5 (0.81) | S1PR5S1PR1FUCA1 | |
| SCHEMBL565212 | 0.84 | S1PR5 (0.87) | S1PR5S1PR1FUCA1 | |
| Hydrochloric Acid SCHEMBL20488123 | 0.84 | FUCA1 (0.58) | S1PR5S1PR1FUCA1MEN1ALDH1A1 | |
| SCHEMBL6749184 | 0.84 | S1PR5 (0.50) | S1PR5S1PR1FUCA1HSD11B1GRIN2B | |
| SCHEMBL7148453 | 0.83 | S1PR5 (0.51) | S1PR5S1PR1FUCA1HSD11B1GRIN2B | |
| SCHEMBL2955795 | 0.82 | FUCA1 (0.60) | S1PR5S1PR1FUCA1ALDH1A1 | |
| SCHEMBL7147305 | 0.82 | L3MBTL1 (0.56) | MEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL6318888 | 0.81 | S1PR5 (0.53) | S1PR5S1PR1FUCA1HSD11B1GRIN2B | |
| SCHEMBL2330642 | 0.80 | S1PR5 (0.68) | S1PR5S1PR1FUCA1GRIN2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | S1PR5 2019/4885S1PR1 1697/4885FUCA1 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.